Key result
Goal-Directed Therapy with non-invasive hemodynamic monitoring reduced serious perioperative complications to 10% compared to 32% with standard monitoring in patients with placenta praevia accreta.
Why the study?
Given the risk of conspicuous blood loss during cesarean section for major placenta praevia, the study evaluated the impact of goal-directed therapy with non-invasive hemodynamic monitoring on maternal and fetal health.
Does Goal-Directed Therapy with non-invasive hemodynamic monitoring improve maternal and fetal outcomes in patients with placenta praevia accreta undergoing cesarean delivery?
Observational (n=40)
No
Does Goal-Directed Therapy with non-invasive hemodynamic monitoring improve maternal and fetal outcomes in patients with placenta praevia accreta undergoing cesarean delivery?
Absolute Event Rate: 10% vs 32%
p-value: p=0.04
Goal-directed fluid therapy guided by non-invasive hemodynamic monitoring during cesarean delivery for placenta praevia accreta may reduce postoperative complications, blood product usage, and maternal lactate levels.
May support goal-directed monitoring in accreta cesareans; hypothesis-generating and requires RCTs before practice change.
BACKGROUND: We carry out a retrospective observational analysis of clinical records of patients with major placenta praevia who underwent cesarean section surgery over a period of 20 months in our hospital. Out of a total of 40 patients, 20 were subjected to Goal-Directed Therapy (GDT) implemented with non-invasive hemodynamic monitoring using the EV1000 ClearSight system (Group I) and 20 to standard hemodynamic monitoring (Group II). Given the risk of conspicuous blood loss, this study evaluate the impact on maternal and fetal health of GDT relative to standard hemodynamic monitoring. RESULTS: Average total infusion of fluids was 1600 +/- 350 ml. Use of blood products occurred in 29 patients (72,5%), of which 11 had a hysterectomy and 8 were treated with Bakri Balloons. For 2 patients > 1000 mL of concentrated red blood cells were used. When stroke volume index SVI dropped below 35 mL/m2/beat, it responded well to the infusion of at least 2 crystalloid boluses (5 ml/kg) in 7 patients. Cardiac index (CI) increased in 8 patients in concomitance with a reduction in medium arterial pressure (MAP), but the use of ephedrine (10 mg iv) re-established acceptable baseline values. Group I means are higher than Group II means for MAP, lower for RBC usage, end-of-surgery maternal lactates and fetal pH, and for LOS. Statistical analysis determines that the null hypotheses of equalities between Groups I and II can be rejected for all measures apart from MAP at baseline and induction. Proportions of serious complications in Groups I and II are respectively 10% and 32% and Boschloo's test rejects the null of equality of proportions against the alternative hypothesis of lower proportion of occurrence in Group I than in Group II. CONCLUSIONS: Hypovolemia can lead to vasoconstriction and inadequate perfusion with decreased oxygen delivery to organs and peripheral tissues and ultimately cause organ dysfunction. Despite the small sample size due to the rarity of the pathology, our statistical analysis finds evidence in favor of more favorable clinical outcomes for patients who received GDT implemented with non-invasive hemodynamic monitoring infusion relative to patients who received standard hemodynamic monitoring.
No takes yet. Share an insight, caveat, or question.
Loreto et al. (2022) conducted an observational in Placenta praevia accreta (n=40). Goal-Directed Therapy with non-invasive hemodynamic monitoring vs. Standard hemodynamic monitoring was evaluated on Serious perioperative complications (p=0.04). Goal-Directed Therapy with non-invasive hemodynamic monitoring reduced serious perioperative complications to 10% compared to 32% with standard monitoring in patients with placenta praevia accreta.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: